ArticleAMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science2025
Major Cardiovascular and Renal Complications in IgA Vasculitis: Insights from a Federated Health Research Network.
Article in AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gut microbiota in Henoch-Schönlein purpura: from pathogenesis to therapeutic strategies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IgA Vasculitis (IgAV) is an immune-mediated condition with limited data on its long-term prognosis in adults. This study utilized the federated TriNetX network to evaluate the incidence of cardiac, renal, and vascular complications in adults diagnosed with IgAV. After propensity score matching, 12,506 patients with IgAV and 12,506 controls were analyzed. Over 6-month, 1-year, and 3-year periods, patients with IgAV had significantly higher risks of myocardial infarction, atrial fibrillation, stroke, pulmonary embolism, venous thromboembolism, chronic kidney disease, and end-stage renal disease compared to controls. Chronic kidney disease was the most common complication, with a 3-year risk of 8.6% and the highest absolute and relative risk difference. These findings suggest that adults with IgAV may be at increased risk for serious renal and cardiovascular complications, underscoring the need for further study to determine best practices for long term monitoring and management to mitigate morbidity associated with the disease.
Identifiers
40502218PMC12150691What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.